Long-acting injectable HIV therapy versus daily orals - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-acting injectable HIV therapy versus daily orals

  • By

  • Matthew Solan

  • November 5, 2026

  • 3 min

Share

Clinical Scorecard: Long-acting injectable HIV therapy versus daily orals

At a Glance

Category

Detail

Condition

HIV treated with long-acting injectable cabotegravir plus rilpivirine

Key Mechanisms

Injectable therapy offers an alternative to daily oral treatment, which Dr. Ricky Hsu described as potentially contributing to treatment fatigue, adherence challenges and emotional burden.

Target Population

Adults previously receiving oral antiretroviral therapy who switched to injectable cabotegravir plus rilpivirine; reported outcomes focused on initially suppressed patients who completed initiation.

Care Setting

Routine HIV care evaluated through an observational OPERA cohort analysis

Key Highlights

  • The analysis included 7,995 adults who switched between January 21, 2021, and December 31, 2025, with follow-up through February 28, 2026.

  • At initiation, 6,955 patients (87%) had viral loads below 50 copies/mL. Of these, 6,362 completed initiation.

  • Among those completing initiation, 77% remained in care and on injectable therapy at study end, with or without interruptions. Median treatment duration was 18 months.

  • During the first uninterrupted treatment course, 94% had a viral load below 50 copies/mL at their last measurement; 81% were below that threshold at every measurement.

  • Confirmed virologic failure occurred in 1%.

  • Among 182 surveys of provider-confirmed discontinuations, leading reasons were nonadherence to injection visits (29%), loss to care (23%) and a desire to switch to oral therapy (15%).

Guideline-Based Recommendations

The source reports observational findings and expert comments rather than a clinical guideline.

Diagnosis

  • The article does not provide HIV diagnostic recommendations.

  • Viral load below 50 copies/mL at initiation identified the suppressed subgroup described in the outcome analysis.

Management

  • The analysis evaluated outcomes after switching from oral therapy to injectable cabotegravir plus rilpivirine.

  • The article does not provide treatment-selection criteria, drug doses or prescribing schedules.

  • Dr. Hsu suggested that long-acting treatment may offer patients a sense of control and empowerment; this was an expert comment rather than a measured study outcome.

Monitoring & Follow-up

  • Outcomes included treatment persistence, viral suppression, injection timing and confirmed virologic failure.

  • Completion of initiation required the first two injections no more than 67 days apart.

  • Discontinuation was defined as more than 127 days without an injection.

  • Confirmed virologic failure required two consecutive viral loads of at least 200 copies/mL or one result at that threshold followed by discontinuation.

Risks

  • Physicians’ questions included treatment persistence, injection-site tolerability and effectiveness in routine care.

  • The article does not report injection-site reaction frequency.

  • Nonadherence to injection visits and loss to care were reported reasons for discontinuation.

  • Provider surveys represented only 10% of discontinuations.

Patient & Prescribing Data

The source reported a median age of 37 years; 23% were aged 50 or older, 86% were male, 43% were Black and 32% were Hispanic. Most patients (78%) had CD4 counts of at least 500 cells/µL. Median time on the previous regimen was 21 months.

According to Dr. Hsu, 95% received injections on time or had only one late injection within 5 days of the recommended window.

The 94% suppression finding referred to the last measurement during the first uninterrupted treatment course, rather than suppression at every measurement. The corresponding every-measurement figure was 81%.

Clinical Best Practices

  • Interpret the results within the initially suppressed subgroup that completed initiation.

  • Distinguish remaining on treatment with or without interruptions from outcomes during the first uninterrupted course.

  • Treat initiation, discontinuation and virologic failure thresholds as study definitions rather than independent prescribing recommendations.

  • Recognize that the observational analysis was not a randomized comparison with continued daily oral therapy.

  • The supplied article reported that the abstract did not include financial disclosures or conflict-of-interest statements.

Related Resources & Content

  • Long-acting injectable HIV therapy versus daily orals — Matthew Solan — IDSA Reporter — November 5, 2026 — Source article.

  • High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort — Hsu RK, Sension MG, Fusco JS, et al — IDWeek 2026, conference presentation — October 21–24, 2026, Washington, DC — Presentation materials.

Original Source(s)

Related Content